TM-25659
|
|
|
- CAS號:
- 260553-97-7
- 英文名:
- TM-25659
- 英文別名:
- TM-25659;TM 25659,TM25659;3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-5-methyl-6-(pyridin-3-yl)-3H-imidazo[4,5-b]pyridine;3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-5-methyl-6-(pyridin-3-yl)-3H-imidazo[4,5-b]pyridine;3H-Imidazo[4,5-b]pyridine, 2-butyl-5-methyl-6-(3-pyridinyl)-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
- 中文名:
- TM-25659
- 中文別名:
- 化合物 T13169;化合物TM-25659;3-((2'-(2H-四唑-5-基)-[1,1'-聯(lián)苯]-4-基)甲基)-2-丁基-5-甲基-6-(吡啶-3-基)-3H-咪唑并[4,5-B]吡啶;3-((2'-(2H-四唑-5-基)-[1,1'-聯(lián)苯]-4-基)甲基)-2-丁基-5-甲基-6-(吡啶-3-基)-3H-咪唑并[4,5-B]吡啶
- CBNumber:
- CB84845065
- 分子式:
- C30H28N8
- 分子量:
- 500.6
- MOL File:
- 260553-97-7.mol
|
|
|
TM-25659化學(xué)性質(zhì)
-
沸點:
-
768.0±70.0 °C(Predicted)
-
|
-
密度:
-
1.29±0.1 g/cm3(Predicted)
-
|
-
儲存條件:
-
Store at -20°C
-
|
-
溶解度:
-
DMSO : ≥ 135 mg/mL (269.68 mM);Water : < 0.1 mg/mL (insoluble)
-
|
-
形態(tài):
-
Solid
-
|
-
酸度系數(shù)(pKa):
-
4.15±0.10(Predicted)
-
|
-
顏色:
-
White to off-white
-
|
TM-25659性質(zhì)、用途與生產(chǎn)工藝
TM-25659是 具有PDZ結(jié)合基序的轉(zhuǎn)錄共激活子 (TAZ) 的調(diào)制劑。抗骨質(zhì)疏松和抗肥胖活性。
TM-25659 (2, 10, 20, 100 μM) enhances nuclear TAZ localization in a dose-dependent manner and attenuates PPARγ-mediated adipocyte differentiation by facilitating PPARγ suppression activity of TAZ.
TM-25659 (2, 10, 50 μM) enhances osteogenic gene expression and thereby increases osteoblast differentiation.
Cell Proliferation Assay
|
Cell Line:
|
3T3-L1 cells
|
|
Concentration:
|
2, 10, 20, 100 μM
|
|
Incubation Time:
|
6 days
|
|
Result:
|
Acted as a suppressor of PPARγ-dependent adipocyte differentiation
[1]
.
|
TM-25659 (50 mg/kg, i.p., every other day for 2 weeks) suppresses bone loss
in vivo
and decreases weight gain in an obesity model.
TM-25659 has a favourable pharmacokinetic profile in rats. The plasma concentration of TM-25659 declines with an approximate t
1/2
of 7 or 10 h following i.v or p.o. administration respectively. The systemic clearance (CL) is 0.21 L×h
-1
×kg
-1
and the volume of distribution at steady-state (1.91 L×h
-1
×kg
-1
) is larger than the volume of total body fluids.
|
Animal Model:
|
C57BL6 mice (4- to 6-week-old )
|
|
Dosage:
|
50 mg/kg
|
|
Administration:
|
I.p., every other day for 2 weeks
|
|
Result:
|
Attenuated weight gain in these obese mice
[1]
.
|
|
Animal Model:
|
Adult male Sprague-Dawley rats
|
|
Dosage:
|
10 mg/kg
|
|
Administration:
|
I.v. (2, 10 and 30 min), oral (15 and 30 min, and 1, 2, 4 and 8 h)
|
|
Result:
|
Oral administration for 4 weeks moderately but significantly attenuated weight gain and partly restored BMD in the OVX rats
[1]
.
|
TM-25659
上下游產(chǎn)品信息
上游原料
下游產(chǎn)品
| 更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS編號 | 包裝 | 價格 |
|---|
| 2024/11/08 | HY-112920 | TM-25659
TM-25659 | 260553-97-7 | 5mg | 950元 |
| 2024/11/08 | HY-112920 | TM-25659
TM-25659 | 260553-97-7 | 10mM * 1mLin DMSO | 1050元 |
260553-97-7, TM-25659 相關(guān)搜索:
- 化學(xué)試劑
- 抑制劑
- C30H28N8
- 3-((2'-(2H-四唑-5-基)-[1,1'-聯(lián)苯]-4-基)甲基)-2-丁基-5-甲基-6-(吡啶-3-基)-3H-咪唑并[4,5-B]吡啶
- 化合物TM-25659
- 化合物 T13169
- 3-((2'-(2H-四唑-5-基)-[1,1'-聯(lián)苯]-4-基)甲基)-2-丁基-5-甲基-6-(吡啶-3-基)-3H-咪唑并[4,5-B]吡啶
- 260553-97-7
- 3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-5-methyl-6-(pyridin-3-yl)-3H-imidazo[4,5-b]pyridine
- 3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-5-methyl-6-(pyridin-3-yl)-3H-imidazo[4,5-b]pyridine
- TM 25659,TM25659
- 3H-Imidazo[4,5-b]pyridine, 2-butyl-5-methyl-6-(3-pyridinyl)-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
- TM-25659